ANCA相关血管炎肺泡出血:PEXIVAS随机对照试验国际研究结果
PEXIVAS试验纳入704例ANCA相关血管炎患者,191例(27.1%)存在弥漫性肺泡出血(DAH),其中61例为重型(29例接受机械通气)。DAH患者1年死亡率12.0%,无DAH患者6.6%;DAH亚组中血浆置换与无血浆置换、减量激素与标准剂量激素的死亡率差异均未达统计学显著性。
要点
- DAH患者更年轻、更常复发、PR3-ANCA阳性,且更常接受透析。
- DAH患者1年死亡率为12.0%,高于无DAH患者的6.6%。
- DAH亚组中血浆置换或激素剂量对死亡率的影响未达统计学显著性。
核心结论
- ANCA相关血管炎合并DAH患者与无DAH患者在多方面存在差异。
- 需要进一步数据来确认或反驳血浆置换或激素剂量对死亡率的获益。
研究设计与样本
- PEXIVAS(NCT00987389)是ANCA相关血管炎领域最大规模的随机对照试验,首次纳入需要机械通气的DAH患者。
- 704例参与者随机接受血浆置换或无血浆置换,以及减量或标准剂量糖皮质激素。
- DAH状态在入组时定义:无DAH、非重型或重型(脉氧饱和度≤85%或使用机械通气)。
主要发现
- 入组时191例(27.1%)存在DAH,其中61例为重型,包括29例接受机械通气。
- DAH患者更年轻、更常复发、PR3-ANCA阳性,血清肌酐更低但更常接受透析。
- DAH患者中,血浆置换组8/95(8.4%)在1年内死亡,无血浆置换组15/96(15.6%)死亡(HR 0.52;95%CI 0.21-1.24)。
- DAH患者中,减量激素组13/96(13.5%)在1年内死亡,标准剂量激素组10/95(10.5%)死亡(HR 1.33;95%CI 0.57-3.13)。
- 接受机械通气者中,血浆置换与无血浆置换的无呼吸机天数中位数分别为25(IQR 22-26)与22-27;减量激素组中位23(IQR 20-25)少于标准剂量激素组中位26(IQR 25-28)。
临床怎么用
- 对ANCA相关血管炎患者应评估DAH状态,DAH患者1年死亡风险高于无DAH患者。
- DAH亚组中血浆置换或激素剂量对死亡率的效应未达统计学显著性,临床决策需个体化。
局限性
- DAH亚组样本量有限,死亡率比较的置信区间较宽。
- 需要进一步数据确认或反驳血浆置换或激素剂量对死亡率的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). The PEXIVAS (Plasma Exchange and Glucocorticoids in Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis) (NCT00987389) trial was the largest in AAV and the first to enroll participants with DAH requiring mechanical ventilation. Objectives: Evaluate characteristics, treatment effects, and outcomes for patients with AAV with and without DAH. Methods: PEXIVAS randomized 704 participants to plasma exchange (PLEX) or no-PLEX and reduced or standard-dose glucocorticoids (GC). DAH status was defined at enrollment as no-DAH, nonsevere, or severe (room air oxygen saturation of ⩽ 85% as measured by pulse oximetry, or use of mechanical ventilation). Measurements and Main Results: At enrollment, 191 (27.1%) participants had DAH (61 severe, including 29 ventilated) and were younger, more frequently relapsing, PR3 (proteinase 3)-ANCA positive, and had lower serum creatinine but were more frequently dialyzed than participants without DAH (n = 513; 72.9%). Among those with DAH, 8/95 (8.4%) receiving PLEX died within 1 year versus 15/96 (15.6%) with no-PLEX (hazard ratio, 0.52; confidence interval [CI], 0.21-1.24), whereas 13/96 (13.5%) receiving reduced GC died versus 10/95 (10.5%) with standard GC (hazard ratio, 1.33; CI, 0.57-3.13). When ventilated, ventilator-free days were similar with PLEX versus no-PLEX (medians, 25; interquartile range [IQR], 22-26 vs. 22-27) and fewer with reduced GC (median, 23; IQR, 20-25) versus standard GC (median, 26; IQR, 25-28). Treatment effects on mortality did not vary by presence or severity of DAH. Overall, 23/191 (12.0%) with DAH died within 1 year versus 34/513 (6.6%) without DAH. End-stage kidney disease and serious infections did not differ by DAH status or treatments. Conclusions: Patients with AAV and DAH differ from those without DAH in multiple ways. Further data are required to confirm or refute a benefit of PLEX or GC dosing on mortality. Original clinical trial registered with www.clinicaltrials.gov (NCT00987389).
引用
- Fussner LA, Flores-Suárez LF, Cartin-Ceba R, et al. Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS). Am J Respir Crit Care Med. 2024. PMID: 38346237. doi:10.1164/rccm.202308-1426OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。